Douglas G. McNeel, MD, PhD close
Douglas G. McNeel, MD, PhD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Douglas G. McNeel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. McNeel is a genitourinary medical oncologist with a clinical and research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials.


Medical Oncology

Bladder Cancer

Genitourinary Cancer (Bladder, Kidney, Prostate, Testicular)

Kidney Cancer

Prostate Cancer

Testicular Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Fred Hutchinson Cancer Research Center, Seattle, WA
University of Washington Medical Center, Seattle, WA
Residency University of Washington Medical Center, Seattle, WA
Internship University of Washington School of Medicine, Seattle, WA
Medical School University of Chicago, Pritzker School of Medicine, Chicago, IL

Languages Spoken

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Potluri HK Ng TL Newton MA Zhang J Maher CA Nelson PS McNeel DG Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. J Immunother Cancer . 2020 Dec;8(2)
[PubMed ID: 33335027]
Kyriakopoulos CE Eickhoff JC Ferrari AC Schweizer MT Wargowski E Olson BM McNeel DG Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. Clin Cancer Res . 2020 Oct 1;26(19):5162-5171
[PubMed ID: 32513836]
Gamat-Huber M Jeon D Johnson LE Moseman JE Muralidhar A Potluri HK Rastogi I Wargowski E Zahm CD McNeel DG Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancers (Basel) . 2020 Sep 30;12(10)
[PubMed ID: 33008010]
Sullivan JA AlAdra DP Olson BM McNeel DG Burlingham WJ Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. Front Immunol . 2020;11:1867
[PubMed ID: 32983104]
Gamat-Huber M McNeel DG Androgen deprivation as a tumour-immunomodulating treatment. Nat Rev Urol . 2020 Jul;17(7):371-372
[PubMed ID: 32355324]
Madan RA Antonarakis ES Drake CG Fong L Yu EY McNeel DG Lin DW Chang NN Sheikh NA Gulley JL Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst . 2020 Jun 1;112(6):562-573
[PubMed ID: 32145020]
Ascierto PA Fox BA Urba WJ Anderson AC Atkins MB Borden EC Brahmer JR Butterfield LH Cesano A Chen DC de Gruijl TD Dillman RO Drake CG Emens LA Gajewski TF Gulley JL Stephen Hodi FJ Hwu P Kaufman D Kaufman HL Lotze MT McNeel DG Margolin KM Marincola FM Mastrangelo MJ Maus MV Parkinson DR Romero PJ Sondel PM Spranger S Sznol M Weiner GJ Wigginton JM Weber JS Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer . 2020 Apr;8(1)
[PubMed ID: 32300051]
McNeel DG Eickhoff JC Johnson LE Roth AR Perk TG Fong L Antonarakis ES Wargowski E Jeraj R Liu G Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol . 2019 Dec 20;37(36):3507-3517
[PubMed ID: 31644357]
Zahm CD Johnson LE McNeel DG Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunol Immunother . 2019 Oct;68(10):1661-1669
[PubMed ID: 31606777]
Ehlerding EB Lee HJ Barnhart TE Jiang D Kang L McNeel DG Engle JW Cai W Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with <sup>89</sup>Zr-Df-Atezolizumab. Bioconjug Chem . 2019 May 15;30(5):1434-1441
[PubMed ID: 30973703]
Scarpelli M Zahm C Perlman S McNeel DG Jeraj R Liu G FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer . 2019 Jan 30;7(1):23
[PubMed ID: 30700328]
Ehlerding EB Lee HJ Jiang D Ferreira CA Zahm CD Huang P Engle JW McNeel DG Cai W Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. Am J Cancer Res . 2019;9(1):53-63
[PubMed ID: 30755811]
Zahm CD Colluru VT McIlwain SJ Ong IM McNeel DG TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8<sup>+</sup> T Cells. Cancer Immunol Res . 2018 Nov;6(11):1364-1374
[PubMed ID: 30201735]
McNeel DG Eickhoff JC Wargowski E Zahm C Staab MJ Straus J Liu G Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget . 2018 May 22;9(39):25586-25596
[PubMed ID: 29876010]
Johnson LE Brockstedt D Leong M Lauer P Theisen E Sauer JD McNeel DG Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and <i>Listeria</i> vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. Oncoimmunology . 2018;7(8):e1456603
[PubMed ID: 30221049]
Miller JS Morishima C McNeel DG Patel MR Kohrt HEK Thompson JA Sondel PM Wakelee HA Disis ML Kaiser JC Cheever MA Streicher H Creekmore SP Waldmann TA Conlon KC A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clin Cancer Res . 2018 Apr 1;24(7):1525-1535
[PubMed ID: 29203590]
Wargowski E Johnson LE Eickhoff JC Delmastro L Staab MJ Liu G McNeel DG Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer . 2018 Mar 13;6(1):21
[PubMed ID: 29534736]
McNeel DG Therapeutic Cancer Vaccines: How Much Closer Are We? BioDrugs . 2018 Feb;32(1):1-7
[PubMed ID: 29285731]
England CG Jiang D Ehlerding EB Rekoske BT Ellison PA Hernandez R Barnhart TE McNeel DG Huang P Cai W <sup>89</sup>Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging . 2018 Jan;45(1):110-120
[PubMed ID: 28821924]
Kelly M McNeel D Fisch P Malkovsky M Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunol Lett . 2018 Jan;193:1-10
[PubMed ID: 29129721]